# Question 74: The Missing Risk in the Consent Form

## Your role

You are outside counsel to NovaCrest Research, sponsor of a five-site medical-device study. A known material risk was omitted from one consent-form version. Give the exact stop, report, investigation, and re-consent sequence while the scope remains unknown.

## Governing law

Assume the following research rules apply:

1. A subject must give valid informed consent before any research intervention. Consent must disclose reasonably foreseeable material risks identified in the approved protocol.

2. When a sponsor discovers that a consent form omitted a material risk, it must immediately stop new enrollment and nonurgent research interventions under the defective form until an ethics board approves corrected materials.

3. Medically necessary care and safety follow-up must continue. A sponsor may not abandon subjects or withhold care merely to preserve a study pause.

4. The sponsor must report material consent noncompliance to the central ethics board within five business days and to the device regulator within seven calendar days after discovery. A site must make any faster local report required by its approved plan; no faster local period is supplied here.

5. An enrolled subject who has not completed study interventions must be re-consented on an approved corrected form before the next nonurgent intervention.

6. A subject who completed interventions must receive new risk information when it may affect safety follow-up or the subject's willingness to permit continued data use. Consent may not be backdated or recreated as though valid disclosure occurred earlier.

7. Previously collected data is not automatically discarded. The ethics board decides continued use after considering risk, subject wishes, scientific integrity, and the nature of the noncompliance.

8. The sponsor must preserve every consent version, signed form, site log, electronic timestamp, communication, and data record. Corrective work must not overwrite the audit trail.

9. The sponsor must determine scope through version-controlled records and direct site confirmation. It may not assume all or no subjects were affected when records are incomplete.

10. Privileged legal analysis may be separated from operational fact gathering, but privilege does not excuse required reporting or factual candor to oversight bodies.

## Facts

NovaCrest studies an implanted nerve-stimulation lead. The approved protocol identifies a 3 percent risk of temporary nerve weakness and requires that risk in consent.

On Wednesday at 10:00 a.m., NovaCrest learned that consent-form version 4.2 omitted the nerve-weakness paragraph because of a document-conversion error. Version 4.1 and version 4.3 contain it.

The study has enrolled 120 subjects at five sites:

* Site A confirms that 38 subjects signed version 4.2.
* Twenty subjects at other sites are confirmed to have signed version 4.1 or 4.3.
* For the remaining 62 subjects, the central database identifies enrollment dates but not consent version. Several signed PDFs have not yet been uploaded.

Twelve subjects are scheduled for implantation during the next 72 hours. Four are confirmed version-4.2 subjects. The consent versions for eight are unknown. Six other subjects need routine safety visits this week. No urgent medical intervention depends on the research schedule.

One version-4.2 subject experienced temporary nerve weakness that resolved after four days. The event was reported through the study's ordinary safety channel, but the subject was not told before implantation that this was a known risk.

The site investigators propose continuing scheduled implants while sending subjects an explanatory email afterward. The chief scientific officer wants staff to replace version 4.2 PDFs in the database with version 4.3 “so the file is clean.”

NovaCrest can convene the central ethics board for an emergency review tomorrow. It has not yet notified the board or regulator.

## Assignment

Provide an ordered plan addressing:

* Immediate enrollment and intervention holds.
* Care and safety follow-up that must continue.
* The ethics-board and regulator reporting clocks.
* Emergency approval of corrected materials.
* Re-consent of subjects awaiting intervention.
* Notice and consent choices for subjects who completed intervention.
* Treatment of previously collected data.
* The specific records needed to determine the affected population.
* The known nerve-weakness event.
* Preservation, privilege, and the proposed PDF replacement.
* The concrete sequence over the next 72 hours and seven days, without assuming the unknown 62-subject scope.

---

---